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Accepted 25 February 2015; Published online 6 March 2015AbstractObjectives: To quantify and compare the treatment effects on three surrogate end points, progression-free survival (PFS), time to pro-
gression (TTP), and tumor response rate (TR) vs. overall survival (OS) based on a meta-analysis of randomized controlled trials (RCTs) of
drug interventions in advanced colorectal cancer (aCRC).
Study Design and Setting: We systematically searched for RCTs of pharmacologic therapies in aCRC between 2003 and 2013. Trial
characteristics, risk of bias, and outcomes were recorded based on a predefined form. Univariate and multivariate random-effects meta-
analyses were used to estimate pooled summary treatment effects. The ratio of hazard ratios (HRs)/odds ratios (ORs) and difference in
medians were used to quantify the degree of difference in treatment effects on the surrogate end points and OS. Spearman r, surrogate
threshold effect (STE), and R2 were also estimated across predefined trial-level covariates.
Results: We included 101 RCTs. In univariate and multivariate meta-analyses, we found larger treatment effects for the surrogates than
for OS. Compared with OS, treatment effects were on average 13% higher when HRs were measured and 3% to 45% higher when ORs
were considered; differences in median PFS/TTP were higher than on OS by an average of 0.5 month. Spearman r ranged from 0.39 to
0.80, mean R2 from 0.06 to 0.65, and STE was 0.8 for HRPFS, 0.64 for HRTTP, or 0.28 for ORTR. The stratified analyses revealed high
variability across all strata.
Conclusion: None of the end points in this study were found to achieve the level of evidence (ie, mean R2trialO 0.60) that has been set to
select high or excellent correlation levels by common surrogate evaluation tools. Previous surrogacy relationships observed between PFS
and TTP vs. OS in selected settings may not apply across other classes or lines of therapy.  2015 Elsevier Inc. All rights reserved.
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0895-4356/ 2015 Elsevier Inc. All rights reserved.of health interventions [1]. In colorectal cancer, the second
commonest cause of cancer-related mortality in high-
income countries [2], predictive end points for overall
survival (OS) are needed to accelerate the availability of
promising new therapies for patients. A number of surro-
gate end points for OS in clinical oncology trials have been
proposed, including progression-free survival (PFS), time
to progression (TTP), and tumor response rate (TR)
[3e5]. However, to ensure that these surrogate end points
provide the same answer as the final end point (OS) about
the experimental therapy, they should undergo a process of
surrogate validation [6]. Several authors have dealt with the
validation of PFS [7e12], TTP [8,10,13], or TR [13,14] as
surrogate end points for OS in advanced colorectal cancer
cal Epidemiology 68 (2015) 833e842What is new?
 The meta-analyses showed that treatment effect
sizes were always larger for the surrogate end
points than for overall survival (OS). The stratified
analyses revealed high variability across all strata.
 Progression-free survival (PFS), time to progres-
sion (TTP), and tumor response rate (TR) have
been proposed as surrogate for OS in advanced
colorectal cancer (aCRC); however, previous sur-
rogacy relationship observed in selected aCRC
therapies may not directly apply across other clas-
ses or lines of therapy.
 None of the end points in this study were found to
achieve the level of evidence that has been set to
select high or excellent correlation levels by com-
mon surrogate evaluation tools. Where PFS and
TTP are deemed acceptable surrogates for OS, pol-
icy makers still need to consider that the antici-
pated treatment effect on OS is likely to be
smaller than that observed on the surrogate mea-
sure when weighing up the evidence in their
licensing and coverage decisions. TR should not
be used as a surrogate end point for OS when eval-
uating the efficacy of drug interventions in aCRC.
(aCRC) over the last decade. Although most of the studies
are of high quality, some are not based on systematic re-
view of the available evidence, either because they were
based on opportunistically available individual-patient data
(IPD) [7,9,11,12,14] or focused on subgroups of trials and
therapies [8,13] and did not, therefore, provide a compre-
hensive examination of the issue. The present study seeks
to overcome these limitations by systematically looking at
all available randomized controlled trials (RCTs), across
drug classes and lines of therapy, and considering different
approaches to surrogate validation, with the primary aim of
quantifying and comparing treatment effects on surrogates
and on OS.
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We conducted and reported this systematic review in
accordance with the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses statement [15].
2.1. Data sources and selection strategy
We searched the following databases from 2003 to January
31, 2013: MEDLINE, EMBASE (via OVID), and the Co-
chrane Central Register of Controlled Trials. A copy of the
bibliographic searches is provided in the SupplementaryMaterial at www.jclinepi.com. We limited our searches to
the last 10 years of drug interventions in metastatic colorectal
cancer to limit the heterogeneity in our sample and, at the same
time, to reflect current clinical practice in most developed
countries. We checked citations in identified studies and sys-
tematic reviews already known to the authors [16] as addi-
tional sources of potentially eligible trials.
Trials were included if they were RCTs in advanced or
metastatic colorectal cancer assessing a pharmacologic
therapy against either a placebo or other drug therapy. Tri-
als had to report OS and either PFS or TTP or TR. We
excluded adjuvant setting trials and trials assessing radio-
therapy, supportive-care drugs, other nonantineoplastic
drugs, nondrug treatments, and trials that were stopped
early, with accrual rate less than 70% of the target sample
size. When multiple publications of the same RCT were
available, only the most recent one reporting both surrogate
and final end points was included. Titles and abstracts were
screened independently by two reviewers, and disagree-
ments were resolved by full-text retrieval and, when neces-
sary, involvement of a third reviewer.
2.2. Data extraction
One reviewer extracted the data using a standardized
form, and a second reviewer independently checked the
extraction. Information collected included: general charac-
teristics of the trial (ie, study design, sample size), patient
characteristics (ie, median age, performance status), treat-
ments under comparison, risk of bias assessment (using
the Cochrane Collaboration tool [17]), and treatment effects
on OS and PFS, TTP, or TR. In multiarm trials, all available
between-arm comparisons were recorded. OS was defined
as the time from randomization to death from any cause,
with patients censored when they are last seen alive or when
they are lost to follow-up [18]; PFS was defined as the time
between randomization and tumor progression (however
defined) or death from any cause; and TTP as the time be-
tween randomization and tumor progression (however
defined), with censoring of patients who died without prior
documentation of progression. Tumor response is based on
objective tumor measurements by imaging methods that
allow the classification of patients with a complete or partial
confirmed best response as responders. Responses are usu-
ally determined according to the Response Evaluation
Criteria in Solid Tumors guidelines [19] or the World Health
Organization recommendations [20].
For OS, PFS, and TTP, the hazard ratio (HR) and median
survival time, together with the 95% confidence intervals
(CIs) for each arm, were recorded whenever available. The
numberof events (ie, deathsor tumorprogressions or tumor re-
sponses) were also recorded to estimate odds ratios (ORs).
2.3. Statistical analyses
We derived the sample size for this present study based
on a previous publication comparing the treatment effects
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relevant outcomes [21]. Using the subgroup of RCTs in this
study assessing drug therapies in oncology, we derived a
summary OR (95% CI) of 0.48 (0.39 to 0.59) and 0.68
(0.61 to 0.77) for evaluating surrogate or final primary
end points, respectively. To detect this observed relative
difference of 29% in the ORs for surrogate compared with
the final outcomes at 80% power and a level of 5%, we
estimated we would require a total of 114 trials (38 trials
for each surrogate end point, that is, PFS, TTP, TR).2.4. Estimation of pooled treatment effects
We compared treatment effects on OS and treatment ef-
fects on the surrogate end points using several analytical
approaches.
For each individual trial, ORs and HRs were expressed
so that a value less than 1.0 indicated beneficial effect of
the intervention compared with control. To exploit all avail-
able data in trial reports, we also considered median survival
time differences across arms: a positive difference in median
survival time on absolute scale indicates a more favorable
effect of intervention than control. Using each of these three
treatment effect metrics (ORs, HRs, and median differ-
ences), separate der Simonian and Laird random-effects uni-
variate meta-analyses were used to calculate the pooled
treatment effect (95% CI) for OS and each of the three sur-
rogate end points across included trials. Statistical heteroge-
neity as expressed by the I2 statistic was examined [22], and
Egger’s or Harbord’s tests were used to assess potential
small-study effects and publication bias for all outcomes
[23,24]. We also performed separate random-effects multi-
variate meta-analyses. Multivariate meta-analysis combines
estimates of several related parameters over several studies.
In this case, to estimate pooled treatment effects taking into
account the within-trial relationship between OS and each of
the three surrogate end points we used the Stata ‘‘mvmeta’’
command [25]. As we did not have access to IPD, we
assumed within-study correlations varying between 0 and
1.0 and checked the likelihood of each attributed correlation
value from previous IPD meta-analyses, which explored the
association between surrogate end points and OS in metasta-
tic colorectal cancer [7].2.5. Comparison of OS and surrogate end points
treatment effects
We sought to compare treatment effects on OS and on the
surrogate end points by estimating the ratio of HRs (RHR),
ratio of ORs (ROR), and difference in the absolute differ-
ences (DAD) in median survival times. Where an RHR
(for PFS and TTP) or ROR (for tumor progression and
response) is greater than 1.0 and DAD in median survival
times is lower than 0, a more beneficial intervention effect
for the surrogate end point than for OS is implied. We im-
plemented a univariate meta-regressionebased approachproposed [26] to calculate the ROR that was extended to
calculate RHR and DAD [27]. Because this method is based
on HRs, ORs, and differences in medians for OS and surro-
gate end points that are independent, being derived from
separate trials, in our primary analysis, we calculated the
within-trial RHR, ROR, and DAD (for each individual trial
difference in OS and surrogates) using the indirect treatment
comparison approach [28]. These within-trial estimates
were then pooled across trials using random-effects univar-
iate meta-analyses. For multiarm trials, we selected one of
the available comparisons to contribute data to our primary
analyses based on clinical judgment and without regard to
any correlation between surrogate end points and OS. All
analyses were then repeated using all available comparisons
from multiarm trials. Because included RCTs did not have a
common control therapy, we determined in advance for each
study which arm would be the reference group and the
experimental group, taking into account the innovativeness
of the regimen, common oncology practice, and number
of combined agents in additive comparisons.
2.6. Surrogacy metrics
In addition, we calculated commonly used indicators of
surrogacy validity [16]: Spearman r correlation coefficient
[10,29,30], the R2trial (95% CI) for the relationship between
the treatment effects on the surrogate and the final out-
comes variables on the log scale derived from a weighted
least-squares regression [7,13,31e33], and the surrogate
threshold effect (STE), that is, the intercept of the regres-
sion line with zero effect on OS [34].
2.7. Stratification according to trial-level covariates
To assess how surrogacy indicators might vary across
included trials, we stratified our analyses according to a pre-
defined set of trial-level covariates: type of intervention (sys-
temic chemotherapy vs. other agents), type of comparison
(additive vs. other type of comparisons), and comparator
(active vs. inactive, that is, placebo or best supportive care),
stage of therapy (first line vs. other lines of therapy), study
design (superiority vs. other), a balanced use of postrandom-
ization therapies or crossover (low other bias factors vs. high/
unclear other biases), type of primary end point (final vs. sur-
rogate), phase of the study (III/IV vs. II), funding source (for
profit vs. other), center status (multicenter vs. single center).
Data were assumed to be missing at random, and no data
imputation was undertaken. Data analyses were performed
in Stata 12 StataCorp LP, College Station, Texas, USA.3. Results
3.1. Characteristics of included RCTs
In total, 101 RCTs were included that reported 117
trial arm comparisons and randomized 40,243 patients
Fig. 1. Flow diagram of study selection process.
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Material at www.jclinepi.com). Table 1 provides a sum-
mary of trial and patients characteristics. The publication
years spanned 2003 and 2012, with a maximum of 15
publications in year 2011. On average recruitment periods
lasted 29 months and publications occurred approximately
4 years after the start of recruitment. The stated primary
end point was OS or survival rate in 27 (27%) of all trials,
the remainder defining the primary outcome as either a
surrogate (25% PFS, 32% TR, 6% TTP) or toxicity
(4%) end point. As a result of the randomization, all pop-
ulation characteristics and performance status [35]
seemed well balanced across the study arms (data not
shown). The RCTs that assessed systemic chemotherapy
alone contained one or more among fluoropyrimidines
(fluorouracil, capecitabine, tegafur, doxifluridine), irinote-
can, or oxaliplatin. A few studies had additional chemo-
therapeutic agents, such as raltitrexed, methotrexate,
pemetrexed, cisplatin, mitomycin C, and vincristine. For
hepatic intra-arterial chemotherapy, floxuridine was the
agent most commonly used. The most frequent anti-
angiogenic compound was bevacizumab, whereas the
anti-EGFR agents assessed in RCTs were cetuximab, pan-
itumumab, or gefitinib. Finally, the targeted agents not
belonging to the previous two categories were celecoxib,perifosine, tipifarnib, and the anticarcinoembryonic anti-
gen antibody (3H1).3.2. Risk of bias assessment
A number of trials failed to provide sufficient detail to
assess their potential risk of bias (Table 2). Where details
were provided, all trials reported evidence of appropriate
methods for random sequence generation and allocation
concealment. A number of trials (N 5 43) were described
as ‘‘open label’’ and therefore considered at risk of bias
due to lack of blinding of participant and clinical
personnel. However, several trials (N 5 26) stated proce-
dures for independent blinded assessment of tumor
response or progression. Few trials (N 5 7) reported sub-
stantive (O20%) data losses at follow-up or failed to
report the outcome findings for all specified outcomes
(N 5 8). Sixteen publications (16%) reported that treat-
ment crossover across arms in the trial was allowed,
whereas use of postprogression therapies was reported in
54 (53%). In 14 of these cases, there appeared to be sub-
stantive imbalance in postprogression therapy between
intervention and control groups likely to result in perfor-
mance bias that is a systematic difference between groups
in the care that is provided.
Table 1. Characteristics of 101 included RCTs
Study characteristics N (%)
Phase:
II 34 (34)
IIIeIV 67 (66)
Study design:
Superiority 60 (59)
Equivalence or Noninferiority 14 (14)
Noncomparative studies 27 (27)
N arms:
2 84 (83)
3 13 (13)
O3 4 (4)
Funding source:
For profit 47 (46)
Not for profit 20 (20)
Mixed or not reported 34 (34)
Setting
International 29 (29)
Europe 15 (15)
Uninational 57 (56)
Center status:
Multicenter 95 (94)
Single center 6 (6)
Median follow-up (mo) 24 (7.5e60.6)a
Patients randomized 290 (35e2,035)a
Median age 62 (50e75)a
Male proportions 0.61 (0.08e0.79)a
Line of therapy:
First 76 (75)
Second or mix firstesecond 20 (20)
Third or mix secondethird 5 (5)
Treatment:
Systemic chemotherapy 56 (55)
Anti-EGFR antibodies 15 (15)
Angiogenesis inhibitors 20 (20)
Other molecular-targeted agents 5 (5)
IHA chemotherapy 5 (5)
Comparator:
Active 87 (86)
Inactive 14 (14)
Type of comparison:
Additiveb 47 (47)
Substitutive 31 (31)
Other 23 (23)
Abbreviations: RCT, randomized controlled trial; anti-EGFR, anti-
epidermal growth factor receptor; IHA, intrahepatic arterial.
Values are numbers (percentages) unless otherwise stated.
a Median (range).
b Additive comparison when treatment is compared with the same
one plus an additional agent, substitutive comparison where one of
the agents in the association is substituted by another one, and other
comparisons for the remainder, including different schedules or ways
of administration.
Table 2. Risk of bias assessment
Domain Low Unclear High
Random sequence generation 30 (30) 71 (70) d
Allocation concealment 34 (34) 67 (66) d
Blinding of participants and personnel 11 (11) 47 (46) 43 (43)
Blinding of outcome assessment 26 (26) 58 (57) 17 (17)
Incomplete outcome data 79 (78) 15 (15) 7 (7)
Selective reporting 82 (81) 11 (11) 8 (8)
Use of postprogression therapiesa 28 (28) 59 (58) 14 (14)
Number of trials (percentages) reported.
a Low risk: no postprogression treatment allowed when patients
failed to respond to allocated therapy or subsequent treatment al-
lowed and shown to be similar across arm; high risk: postprogression
treatment allowed and shown to be different across arms.
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Depending on type of end point and metrics (HRs,
ORs, or medians) used, 9 to 58 trials contributed to each
pooled treatment-effect estimation. Univariate and multi-
variate random-effects meta-analyses demonstrate a sig-
nificant benefit of the intervention relative to control
for OS and each of the surrogate end points (Table 3
and Table 4). Consistently across HR, OR, and differenceof median survival times, treatment effect sizes were
larger for the surrogate end points than for OS. The
multivariate meta-analyses gave broadly similar esti-
mates to univariate meta-analyses (Table 4). Estimates
of between-study covariance decrease as the assumed
within-study correlation increases, suggesting between-
study variance compensates for lack of correlation
between the end points of interest in univariate meta-
analyses.
Moderate to substantial levels of heterogeneity (I2
statistic O 30%) were seen. There was no evidence of
small-study effect bias, except for HRPFS (Egger’s test
bias 5 2.68; P 5 0.022) and difference in median PFS
time (Egger’s test bias 5 1.02; P 5 0.027; Table 3).
3.4. Measures of surrogacy validity
There was evidence of moderate to high correlation [36]
between the treatment effects on OS and on each of the
three surrogate end points (r between 0.39 and 0.80). The
coefficients of determination for the linear relationships
(R2trial) and related 95% CIs are shown in Table 5. Estimated
STEs were consistently lower than 1.0 for HR or OR and
greater than 0 for the difference in medians. For example,
a HRPFS! 0.8 would need to be observed to predict a less
than 1.0 HROS (Table 5).
3.5. Comparison of treatment effects on OS and
surrogate end points
The within-study paired comparison analysis showed
for PFS, TTP, and TR that the estimated RHR and ROR
exceeded 1.0 and the DAD was less than 0.0, indicating
a larger treatment effect on the surrogate end points than
on OS (Table 5). Compared with OS, relative treatment
effects on the surrogate end points were on average
13% higher when HRs were measured and 3% to 45%
higher when ORs were considered. On the absolute scale,
the treatment effects on PFS or TTP were higher than on
OS by an average of 0.5 months. The random-effects lo-
gistic metaregression models provided similar results. In
a sensitivity analysis, 16 additional arm comparisons
Table 3. Summary treatment effectsa on OS, PFS, TTP, or TR
Study
endpoints OS/Deaths PFS TTP TR
HR 0.95 (0.90 to 0.99) P 5 0.030,
I2 5 64.3%
Egger’s test P 5 0.526,
N 5 49
0.84 (0.78 to 0.91) P5 0.000,
I25 83.9%
Egger’s test P5 0.022,
N5 39
0.75 (0.62 to 0.89) P 5 0.002,
I2 5 84.1%
Egger’s test P 5 0.983,
N 5 9
NA
OR 0.95 (0.87 to 1.04) P 5 0.270,
I2 5 27.1%
Harbord’s test P 5 0.602,
N 5 34
NA 0.88 (0.73 to 1.07) P 5 0.203,
I2 5 56.9%
Harbord’s test P 5 0.535,
N 5 17
0.71 (0.64 to 0.80) P5 0.000,
I25 77.7%
Harbord’s test P5 0.129,
N5 95
MD 0.23 (0.44 to 0.90) P5 0.504,
I25 51%
Egger’s test P5 0.630,
N5 58
0.76 (0.45 to 1.06) P5 0.000,
I25 84.9%
Egger’s test P5 0.027,
N5 41
0.56 (0.16 to 1.29) P5 0.130,
I25 71%
Egger’s test P5 0.114,
N5 24
NA
Abbreviations: OS, overall survival; PFS, progression-free survival; TTP, time to progression; TR, tumor response; HR, hazard ratio; NA, not
applicable; OR, odds ratio; MD, median difference.
a Der Simonian and Laird random-effects method. Treatment OR and HR lower than 1.0 correspond to beneficial effects, whereas positive
weighted (by inverse variance) differences in treatment vs. control median survival times correspond to beneficial effects. Effect estimates
(95%CI), P-value for significance of effect size, I2statistic, number of trials, and Egger’s or Harbord’s modified tests for small-study effect reported.
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alyses were replicated without any apparent discrepancy
with the primary analyses reported above (see
Supplementary Material/eTable 1 at www.jclinepi.com).
There was some evidence of a difference in the RHRs
or RORs for OS and the surrogate end points acrossTable 4. Summary treatment effects  results of the multivariate meta-ana
Treatment effect L results of bivariate meta-analysisa
Study endpoints OS vs. PFS
HR vs. HR
(r 5 0) 0.94 (0.90 to 0.99) vs. 0.84 (0.77 to
0.91) [0.99]
0.95 (0.90 to
0.95) [0.78]
(r 5 0.5) 0.95 (0.91 to 0.99) vs. 0.83 (0.76 to
0.91) [0.86]
0.95 (0.91 to
0.94) [0.70]
(r 5 0.75) 0.95 (0.91 to 0.99) vs. 0.83 (0.76 to
0.90) [0.78]
0.95 (0.91 to
0.93) [0.66]
(r 5 0.95) 0.95 (0.91 to 0.99) vs. 0.83 (0.76 to
0.90) [0.71]
0.95 (0.91 to
0.93) [0.61]
OR vs. OR NA
(r 5 0) 0.95 (0.87 to
1.13) [1.00]
(r 5 0.5) 0.96 (0.87 to
1.14) [0.60]
(r 5 0.75) 0.96 (0.88 to
1.13) [0.32]
(r 5 0.95) 0.96 (0.87 to
1.12) [0.1
MD vs. MD
(r 5 0) 0.03 (0.63 to 0.69) vs. 0.68 (0.27 to
1.10) [1.00]
0.15 (0.55 to
1.45) [0.78]
(r 5 0.5) 0.10 (0.58 to 0.78) vs. 0.67 (0.26 to
1.08) [0.90]
0.18 (0.52 to
1.35) [0.60]
(r 5 0.75) 0.21 (0.49 to 0.91) vs. 0.65 (0.24 to
1.06) [0.74]
0.19 (0.50 to
1.28) [0.50]
(r 5 0.95) 0.31 (0.41 to 1.02) vs. 0.65 (0.22 to
1.08) [0.54]
0.20 (0.50 to
1.17) [0.34]
Abbreviations: OS, overall survival; PFS, progression-free survival; TTP,
ratio; MD, median difference.
a Bivariate meta-analyses with residual maximum likelihood estimatio
Between-study covariance reported in squared brackets.predefined trial-level covariate strata. Higher RHRs were
seen for OS vs. PFS for trials with additive comparisons
and for OS vs. TTP for trials with profit funding and inac-
tive comparator. Higher ROR for OS vs. TR was
observed for trials of second or later line therapy, superi-
ority trials, and trials reporting OS as the primary endlyses
OS vs. TTP OS vs. tumor response
NA
0.99) vs. 0.82 (0.70 to
0.99) vs. 0.82 (0.72 to
0.99) vs. 0.82 (0.72 to
0.99) vs. 0.82 (0.73 to
1.04) vs. 0.94 (0.78 to 0.97 (0.88 to 1.06) vs. 0.71 (0.63 to
0.80) [0.50]
1.05) vs. 0.93 (0.76 to 0.97 (0.89 to 1.06) vs. 0.72 (0.64 to
0.80) [0.21]
1.05) vs. 0.92 (0.74 to 0.98 (0.89 to 1.07) vs. 0.72 (0.64 to
0.80) [0.05]
1.05) vs. 0.90 (0.72 to
6]
0.99 (0.90 to 1.08) vs. 0.72 (0.64 to
0.80) [0.09]
NA
0.86) vs. 0.74 (0.02 to
0.88) vs. 0.70 (0.05 to
0.89) to 0.68 (0.07 to
0.90) vs. 0.63 (0.08 to
time to progression; HR, hazard ratio; NA, not applicable; OR, odds
n of outcomes with common assumed within-study correlations (r).
Table 5. Surrogacy validity and comparison of treatment effects between OS/deaths and PFS, TTP, or TR
OS vs. surrogate treatment effect contrasts
Study endpoints OS vs. PFS OS vs. TTP OS vs. tumor response
HR vs. HR within-study
paired analysisa
metaregressionb
1.13 (1.06 to 1.20) P ! 0.001
1.13 (1.02 to 1.25) P 5 0.026
N 5 36
STE 5 0.8
r 5 0.75***
R2 (95%CI) 5 0.34 (0.10, 0.59)
1.13 (1.02 to 1.25) P 5 0.020
1.14 (0.83 to 1.57) P 5 0.389
N 5 9
STE 5 0.61
r 5 0.80***
R2 (95%CI) 5 0.65 (0.09, 0.92)
NA
OR vs. OR within-study
paired analysisa
metaregressionb
NA 1.03 (0.85 to 1.24) P 5 0.754
1.03 (0.76 to 1.39) P 5 0.850
N 5 13
STE 5 0.64
r 5 0.39
R2 (95%CI) 5 0.25 (0, 0.68)
1.45 (1.19 to 1.77) P ! 0.001
1.44 (1.14 to 1.83) P 5 0.003
N 5 32
STE ! 0.28
r 5 0.53***
R2 (95%CI) 5 0.06 (0.01, 0.29)
DAD vs. DAD within-study
paired analysisa
metaregressionb
0.50 (0.85 to 0.16) P ! 0.001
0.19 (1.14 to 0.75) P 5 0.689
N 5 36
STE 5 2
r 5 0.59***
R2 (95%CI) 5 0.52 (0.26, 0.72)
0.52 (1.14 to 0.10) P 5 0.098
1.09 (2.43 to 0.26) P 5 0.110
N 5 21
STE O 4.0
r 5 0.54**
R2 (95%CI) 5 0.43 (0.10, 0.72)
NA
Abbreviations: OS, overall survival; PFS, progression-free survival; TTP, time to progression; TR, tumor response; HR, hazard ratio; STE surro-
gate threshold effect; NA, not applicable; OR, odds ratio; DAD, difference in absolute median difference.
a Der Simonian and Laird random-effects meta-analyses on within-study paired outcomes. For OR and HR, effect estimatesO1.0 correspond to
higher beneficial effects measured on the surrogate. For DAD, effect estimates !0 correspond to higher beneficial effects measured on the sur-
rogate. STE calculated as the value of the treatment effect on the surrogate outcome at which the linear regression prediction bands cross the zero
effect line for the treatment effect on OS. Spearman r correlation coefficient is shown on log variables. *P-value! 0.10, **P-value! 0.05, ***P-
value ! 0.01. R2 derived from least-squares linear regressions on log variables weighted by the inverse of variance.
b Random-effects logistic meta-regressions with residual maximum likelihood estimation for the between-study variance and KnappeHartung
variance estimator for the coefficients. Only trials contributing to the within-study paired analysis considered. Ratio of OR (95%CI) and ratio of HR
(95%CI) O 1.0 and DAD ! 0 correspond to higher beneficial effects measured on the surrogate.
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coefficient and R2trial point estimates also suggests high
variability across identified strata (see Supplementary
Material/eTable 2 at www.jclinepi.com).4. Discussion
Surrogate end points are attractive to measure as they
allow the efficacy of promising treatments to be established
earlier than would be possible if OS had to be observed.
However, to assess whether a new intervention will provide
a significant survival benefit based on the effect on a surro-
gate measure, a reliable and plausible prediction equation
should be estimated. In our systematic review and meta-
analysis of 101 RCTs of pharmacologic interventions in
aCRC published between 2003 and 2013, we found moder-
ate to high levels of correlation (r ranging from 0.39 to
0.80) between treatment effects on OS and treatment effects
on PFS, TTP, and TR. However, the coefficients of determi-
nation for the underlying linear prediction models (R2trial)
were between 0.06 and 0.65, meaning that, in general, less
than half of the variability in the survival benefits could be
explained by the variability in the surrogate treatment ef-
fects. Moreover, the treatment effect observed on the surro-
gate end point appears always to be larger than that
observed on the final end point, by 3% to 45%. A relative
larger treatment effect observed on the surrogate end pointtranslates into an STE as high as 0.8 for HRPFS, 0.64 for
HRTTP, or 0.28 for ORTR to achieve a benefit in terms of
OS.
4.1. Comparison with previous findings
Different techniques and approaches have been proposed
for the evaluation of surrogate end points [37,38]; however,
the hallmark for a valid surrogate is that differences or
changes observed on it must accurately reflect changes in
the final end point [39]. A theoretical verification of a small
treatment effect (expressed as a binary variable) on the final
outcome than on the surrogate outcome even if there is
strong association between the surrogate and the patient-
important outcome has been provided [40]. In a recent pub-
lication [21], treatment-effect estimates in a matched cohort
of RCTs across several diseases were found to be relatively
larger (up to 47%) in RCTs assessing surrogate vs. final
patient-relevant primary end points. Those findings are
confirmed by the results of the present study, where HRPFS,
HRTTP and ORTR were all significantly larger (by 13% to
45%) than HROS and ORdeath derived from the same cohort
of RCTs.
Our results appear generally less supportive of PFS,
TTP, or TR as surrogate measures for OS in aCRC than pre-
vious meta-analyses that have examined this issue. For
PFS, our coefficient of determination (R2trial 5 0.34) was
in line with that estimated by Burzykowski et al. [11]
840 O. Ciani et al. / Journal of Clinical Epidemiology 68 (2015) 833e842(R2trial 5 0.33) but lower than those observed in other
studies, ranging from 0.53 to 0.98 [7e10,12]. Spearman
correlation coefficients, both for HR (r 5 0.75) and differ-
ence in medians (r 5 0.59), were lower than previously re-
ported (r 5 0.82 and 0.74, respectively) [8,9]. However,
although previous studies focused on first-line treatment,
25% of RCTs in our sample relate to further lines of ther-
apy. The STE for HRPFS (0.80) compares to that proposed
by Buyse et al. [7] for fluoropyrimidine-based treatments
(0.86), both higher than that estimated by Burzykowski
and Buyse [12] (0.12).
Fewer studies have explored the relationship between
TTP and OS [8,10,13]. Their estimated r (0.52) and R2trial
(0.32) are comparable to those found in this study
(r 5 0.54; R2trial 5 0.43). Johnson et al. [13] did estimate
an STE of 3.3 months for a clinical trial of 400 patients,
the average sample size in our database, whereas our esti-
mate is above 4 months.
Although our estimated coefficient of determination for
TR (R2trial 5 0.06) is similar to that of Johnson et al. [13]
(R2trial 5 0.10), both are much lower than that reported by
Buyse et al. [14] (R2trial 5 0.38). Their results suggest that
a 50% decrease in the odds of failure to respond corre-
sponds to a 6% decrease in the odds of death, a result more
extreme than that suggested by our ROR metric
(ROR 5 1.45; 95% CI: 1.19, 1.77). On the other hand,
Johnson et al. [13] calculate about 30% difference in
response rate, compared with 0.28 in our study, to observe
a minimal benefit on OS.
The lower level of association between the treatment ef-
fect for surrogate end points and OS seen in this study is
likely to reflect our inclusion of all lines of drug therapy.
In other words, the extrapolation of the results from previ-
ous meta-analyses that focused on particular drug treat-
ments, often only in first-line therapy, is likely to
overestimate the ability of PFS, TTP, and TP to act as sur-
rogate end points for OS across other classes of drug treat-
ment and later lines of therapy in aCRC.4.2. Strengths and limitations of the study
Unlike other authors, we decided to look comprehen-
sively at all RCTs without restrictions on treatment type
[7], line of therapy, or sample size [8,29]. We believe this
choice is appropriate to support any claim about PFS,
TTP, or TR being good surrogate end points for drug treat-
ments in aCRC. To reduce potential bias in the analyses, we
undertook a systematic review with independent applica-
tion of predefined inclusion criteria and data extraction.
Moreover, we focused on all three surrogate end points in
a single study, without combining PFS and TTP [41,42],
and provided the most common metrics proposed for the
validation of surrogate end points [16].
Our study has a number of potential limitations. First
and foremost, we relied on summary data from published
reports of RCTs. Potential drawbacks of aggregate meta-analyses have been highlighted elsewhere [43]. For the spe-
cific purpose of surrogate validation, a limitation of using
summary statistics is that the estimation errors for the treat-
ment effects on the surrogate and the final end point cannot
be fully taken into account. Indeed, the estimation errors on
the end points are generally available in published reports
but not the correlation between them. We did not take ac-
count of these estimation errors in our analyses, and this
may have resulted in systematic bias toward lower mea-
sures of surrogacy than if estimation errors had been taken
into account as in meta-analyses based on IPD [44]. None-
theless, given the substantial costs for sharing clinical
research data [45], meta-analyses based on summary data
appear to be the only feasible way to take into account most
of the available evidence about efficacy of health interven-
tions and, therefore, a useful source of data for the valida-
tion of surrogate end points. In addition, lack of IPD
reduced our flexibility to handle outcome findings. For
instance, not all the trials reported HR (95% CI) for time-
to-event end points although they often reported median
survival times. In an attempt to make use of all available
data, we considered the median survival time and median
survival time differences across arms as equivalent to mean
values of the same distributions. Although median survival
times are not always reliable substitutes for HRs [46], they
are common in meta-analyses of time-to-event variables us-
ing published data [8,10,13,47e49]. Unlike previous aggre-
gate meta-analyses, we sought to take account of the
within-trial correlation of surrogate end points and survival
by performing a multivariate meta-analysis. A previous IPD
meta-analysis of HRPFS as a surrogate for HROS in
fluoropyrimidine-based treatments in aCRC [7] indicates
a reasonable correlation factor lies between 0.75 and
0.95. However, despite findings being consistent across
the wide range of correlation values applied (ie, 0.00 to
0.95), this level of correlation may not hold for other treat-
ments seen in this review. The number of available trials for
each surrogate-to-final outcome comparison was lower than
the sample size calculated ex-ante, yet, for three of the
comparisons performed (HRPFS vs. HROS, HRTTP vs. HROS,
and ORTR vs. ORdeath), the estimated RHRs and ROR were
still significantly different from 1.0.
We found several potential biases in the included trials.
The methodological detail of trials was often poorly re-
ported, in respect of random sequence generation, alloca-
tion concealment, and outcome blinding, and therefore
subject to selection and assessment bias [50]. However, in
our stratified analyses, we combined trials with unclear
and high risk of bias, thus following a conservative
approach. We observed evidence of small-study effect bias
when looking at treatment effects on PFS. However, the ef-
fect disappeared when trials with PFS as primary end point
and those with blinding of outcome assessment were
considered. Finally, we found considerable evidence of sta-
tistical heterogeneity in the treatment effect for OS and sur-
rogate end points across trials. As for clinical heterogeneity,
841O. Ciani et al. / Journal of Clinical Epidemiology 68 (2015) 833e842we circumscribed our study to a recent time span to account
for the marked improvements in the outlook for patients
with metastatic colorectal cancer seen when trials from
the past 10e15 years are compared with those from earlier
periods [51].
4.3. Implications for policy and research
The potential for surrogate end points to impact on
health care policy making and the consequent diffusion of
treatments into oncology practice is shown by the fact that
69 (68%) of all RCTs identified in our sample reported a
surrogate primary outcome. By using a systematic and
comprehensive approach to the identification of drug ther-
apy trials, the findings of our meta-analysis are potentially
more generalizable to the management of aCRC than previ-
ous surrogate validation studies that have focused on spe-
cific drugs or classes of drugs. None of the end points in
this study were found to achieve the level of evidence (ie,
mean R2trialO 0.60) that has been set to select high or excel-
lent correlation levels by common surrogate evaluation
tools [52,53]. Overall, our study shows that TR should
not be used as a surrogate end point for OS when evaluating
drug interventions in aCRC. On the other hand, depending
on the statistical requirements agreed for surrogacy validity,
PFS and TTP might be regarded as acceptable surrogate
measures for OS in aCRC. However, our results indicate
that previous good surrogacy relationship observed in
selected aCRC therapies (eg, fluoruracil plus leucovorin)
may not directly apply across other classes or lines of ther-
apy. Even if applying a lower level of evidence (eg, R2trialO
0.40) such that PFS and TTP can be demonstrated to be
valid surrogates for OS in aCRC, policy makers still need
to consider that the anticipated treatment effect on OS is
likely to be smaller than that observed on the surrogate
measure when weighing up the evidence from use of these
surrogate end points in their licensing and coverage
decisions.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2015.02.016.References
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